Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1509 of 6351
-
Radioactive injection targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \[177Lu\] BL-ARC001 in patients with locally advanced or metas…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Gout and obesity: new trial tests Weight-Loss drug to lower uric acid
Disease control Not yet recruitingA total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a place…
Sponsor: XueMei Guo • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could an old allergy drug help treat depression in seniors?
Symptom relief Recruiting nowThe goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms,…
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New pill aims to tame ulcerative colitis Flare-Ups
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients with active ulcerative colitis.
Phase 2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New daily pill aims to boost growth in kids with dwarfism
Disease control Not yet recruitingThis is a multicenter, non-randomized, open-label, phase I/II study in children with ACH. This study will start with a dose escalation of ABSK061 in children with ACH to evaluate the safety, tolerability, PK, and efficacy. The RDE confirmation part will evaluate the safety and ef…
Phase 1/2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Real-world data on epcoritamab for tough-to-treat lymphoma
Disease control OngoingThis study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Smart sensors and AI aim to spot pregnancy diabetes sooner
Knowledge-focused Not yet recruitingGestational diabetes mellitus (GDM), as the most common metabolic complication of pregnancy, poses a serious threat to maternal and fetal metabolic health. However, current GDM diagnosis faces several problems such as static, single-point, cumbersome to operate and delayed diagno…
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
New cell therapy takes aim at Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec200 in the treatment of relapsed/refractory multiple myeloma.
Early phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can a new pill tame immunotherapy's worst side effects and let patients restart treatment?
Disease control Not yet recruitingThis study is a Phase II, two-cohort, multicenter, two-stage clinical trial. It plans to enroll 72 subjects with solid tumors who discontinued prior ICI therapy due to irAE. Cohort 1 enrolls subjects with irAE resistant to or dependent on corticosteroid therapy. Subjects in Cohor…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a single shot stop c. diff from returning?
Prevention Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.
Phase 2 • Sponsor: AstraZeneca • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New hope for tough anemia: daratumumab trial launches
Disease control Not yet recruitingThis study consists of two phases, phase Ib and phase II. The primary objective of phase Ib is to evaluate the safety and tolerability of multiple doses of daratumumab in patients with refractory aplastic anemia. The primary objective of phase II is to preliminarily assess the ef…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a generic cream match Brand-Name rosacea treatments?
Disease control CompletedThe goal of this clinical trial is to evaluate and demonstrate the therapeutic equivalence and safety of Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1% \& to Placebo for the treatment of moderate to severe facial rosacea.
Phase 1 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for kids with rare metabolic disease: 5-Year trial launches
Disease control Recruiting nowUrea cycle disorders (UCD) are rare diseases in China, would lead to high mortality and disability, which require long-term management due to the recurrent symptoms. This multi-center, prospective, single-arm study was designed to assess the efficacy and safety of Glycerol Phenyl…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New program aims to cut overdose risk for women leaving prison
Disease control By invitation onlyThe overall aim of this study is to reduce overdose risk for criminal legal system (CLS) involved women during community re-entry through the adaptation and testing of an innovative, trauma-informed, relational intervention approach (Trust-Based Relational Intervention or TBRI).
Sponsor: Michele Staton • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug avapritinib under Real-World watch for mastocytosis relief
Disease control Recruiting nowThis is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is …
Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Magnets may replace surgery for some gut blockages
Disease control Recruiting nowEvaluate the performance and safety of the GT Metabolic Magnet System for the creation of side-to-side compression anastomosis in the stomach and/or small bowel in conditions requiring an anastomosis as part of the underlying clinical treatment.
Sponsor: GT Metabolic Solutions, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a phone app tame PTSD? new trial aims to find out
Symptom relief OngoingThis study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
Phase 2 • Sponsor: Oui Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Shorter radiation course for cervical cancer tested in new trial
Disease control Recruiting nowThis study aims to evaluate the efficacy and safety of hypofractionated intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy in patients with cervical cancer. Conventional treatment usually requires 7-8 weeks, which increases the risk of toxicities a…
Phase 2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for AML patients: oral drug aims to keep remission going
Disease control OngoingThe purpose of this study is to assess real-world effectiveness and safety of oral azacitidine in adults diagnosed with acute myeloid leukemia (AML) in Hong Kong
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New bladder cancer drug shows promise in early trial
Disease control Recruiting nowResearchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctor…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC